Loading…
Remedy Meds was cited for unlawfully selling unapproved and misbranded compounded drugs, specifically semaglutide and tirzepatide products, through its website. The company's marketing claims falsely implied that its compounded products were equivalent to FDA-approved drugs (Ozempic, Wegovy, Mounjaro, and Zepbound) by stating they contained "the same active ingredient," violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Since compounded drugs are not FDA-approved, these claims rendered the products misbranded and their distribution constituted prohibited acts under section 301(a) of the FDCA.